Search

Displaying results 4221 - 4230 of 5263 in total
  1. Drug

    Phenolphthalein

    go.drugbank.com/drugs/DB04824
    ApprovedWithdrawn

    Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.

    Mixtures: Herbalax Forte No 70 Tab
  2. Drug

    Ferrous asparto glycinate

    go.drugbank.com/drugs/DB11169
    Approved

    Ferrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

    Mixtures: UltimateCare ONE NF
  3. Drug

    Pexelizumab

    go.drugbank.com/drugs/DB04949
    Investigational

    It is being investigated by Alexion Pharmaceuticals.

  4. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  5. Drug

    OMS906

    go.drugbank.com/drugs/DB17722
    Investigational

    OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.

  6. Drug

    Seliforant

    go.drugbank.com/drugs/DB15220
    Investigational

    Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).

  7. Drug

    Tucidinostat

    go.drugbank.com/drugs/DB06334
    Investigational

  8. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis.

  9. Drug

    CIGB-258 peptide

    go.drugbank.com/drugs/DB15809
    Experimental

    CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant.

  10. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.